Poland· PL-100116001

Zalanzo

A lansoprazole product containing lansoprazolum, registered in Poland by Exeltis Poland Sp. z o.o.. The same ATC class is registered in 19 of our 19 countries.

ATC A02BC03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedZalanzoATCA02BC03REGISTER NO.PL-100116001PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Lansoprazole is registered in 19 of 19 countries.

Countries holding a registration under ATC A02BC03 (lansoprazole), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose

Lansoprazole · ATC A02BC03

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lansoprazole costs, country by country.

Normalised to the WHO defined daily dose (15 mg), the median price runs from $0.15 in France to $0.75 in Switzerland — a ×5.2 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lansoprazole · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.75
  • ES Spain$0.32
  • IT Italy$0.22
  • FR France$0.15
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Lansoprazolum
Manufacturer
Exeltis Poland Sp. z o.o.
Country
Poland (PL)
ATC code
A02BC03
ATC class
Lansoprazole
Defined daily dose
15 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

1 priced
  • gtin
    05909990064045
    28 szt.
    PLN 8.68
  • gtin
    05909990064021
  • gtin
    05909990064038

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

743 interactions on record for lansoprazole.

Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lansoprazole · interactions on record

743 records

  • 24 severe
  • 125 moderate
  • 34 minor
  • 550 info

Most severe, free to view

  • CilostazolB01AC23severe
  • NelfinavirJ05AE04severe
  • AtazanavirJ05AE08severe
  • RilpivirineJ05AG05severe

10 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lansoprazole in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lansoprazole products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Agopton, Lansobene
  • Belgium · Lansoprazol Ab, Lansoprazol Krka
  • Bulgaria · Ланзацид, Ланзопразол Екофарм
  • Cyprus · Lanso
  • Czechia · Lanxib, Lanzul
  • Germany · Lanso Tad, Lansoprazol Abz
  • Denmark · Lansoprazol "doc", Lansoprazol "viatris"
  • Estonia · Lanzostad, Lanzul
  • Spain · Duomate Flas, Estomil
  • Finland · Gasterix, Lansoprazol Krka
  • France · Lansoprazole Almus Pharma, Lansoprazole Arrow
  • United Kingdom (Northern Ireland) · Lansoprazol Activase Pharmaceuticals, Lansoprazole
  • Greece · Lanciprol, Lanso
  • Croatia · Lanzul, Lanzul S
  • Hungary · Emillan, Lansoprazol Teva
  • Ireland · Lansoprazole Accord, Lansoprazole Accord Healthcare Ireland
  • Iceland · Lansoprazol Krka
  • Italy · Ermes, Frilans
  • Lithuania · Lanobax, Lanzostad
  • Luxembourg · Lansoprazol Ratiopharm, Lansoprazole Eg
  • Latvia · Lanzostad, Lanzul
  • Malta · Lanzol
  • Netherlands · Lansoprazol Viatris, Lansoprazole Aurobindo
  • Norway · Lansoprazol Krka, Lansoprazol Medical Valley
  • Portugal · Alexin, Belmural
  • Romania · Lanzul, Levant
  • Sweden · Lansoprazol Krka, Lansoprazol Medical Valley
  • Slovenia · Lanzul
  • Slovakia · Lanzul

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e5099e92-e289-4471-bd16-49554b1259cc
GET /v1/drugs/e5099e92-e289-4471-bd16-49554b1259cc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki dojelitowe, twarde",
  "source": "urpl",
  "strength": "15 mg",
  "packaging": "05909990064021 ¦ Rp ¦ Skasowane ¦ 37126\n7 kaps.\n05909990064038 ¦ Rp ¦ Skasowane ¦ 37127\n14 kaps.\n05909990064045 ¦ Rp ¦ 37128\n28 kaps.",
  "substance": "Lansoprazolum 15 mg",
  "common_name": "Lansoprazolum",
  "pl_product_id": "100116001",
  "pozwolenie_nr": "14044",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about lansoprazole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.